Our study demonstrated that BCR-ABL PEMs might be found in a substantial number of newly diagnosed CP-CML patients if sensitive techniques such as ASO-PCR are used to assess CD34+ stem/progenitor cells, and these PEMs can significantly affect the outcome of imatinib therapy. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.